Exposure metric |
Phase 2 OR6-150
(p value) |
Phase 3 OR6-150
(p value) | |||
Respiratory symptoms: | |||||
Cough | Current | 1.25 (0.056) | 1.27 (0.174) | ||
Cumulative | 1.06 (0.005) | 1.10 (<0.001) | |||
Sputum | Current | 1.18 (0.145) | 1.30 (0.132) | ||
Cumulative | 1.06 (0.236) | 1.03 (0.265) | |||
Cough and sputum | Current | 1.36 (0.024) | 1.32 (0.218) | ||
Cumulative | 1.04 (0.183) | 1.09 (0.005) | |||
Chronic bronchitis | Current | 1.65 (0.009) | 1.42 (0.245) | ||
Cumulative | 1.04 (0.245) | 1.06 (0.199) | |||
Lung function: | β6-151 (p value) | β6-151 (p value) | |||
FEV1 | Current | −0.059 (0.011) | −0.030 (0.317) | ||
Cumulative | −0.004 (0.382) | −0.009 (0.072) | |||
FEF27%–75% | Current | −0.130 (0.015) | −0.103 (0.142) | ||
Cumulative | −0.013 (0.213) | −0.025 (0.025) | |||
FEV1/FVC ratio | Current | −0.758 (0.011) | −0.494 (0.174) | ||
Cumulative | −0.065 (0.265) | −0.147 (0.011) |
↵6-150 ORs for exposure to carbon black (CB) are given for an increase in exposure of 1 mg.m−3 (current exposure) or 100 mg.month.m−3 (cumulative exposure).
↵6-151 Regression coefficients are given in l (FEV1 and FVC), l.s−1 (FEF25–75), or % (FEV1/FVC ratio) for an increase in exposure of 1 mg.m−3 (current exposure) or 100 mg.month.m−3 (cumulative exposure).